Patents matching “antagonist”

US 7632490

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. · Granted Dec 15, 2009 · Expires Dec 10, 2029

US 7629336

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Dec 8, 2009 · Expires Dec 3, 2029

US 7622508

8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

Theravance, Inc. · Granted Nov 24, 2009 · Expires Nov 19, 2029

US 7618630

Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

The Board of Regents of the University of Texas System · Granted Nov 17, 2009 · Expires Nov 12, 2029

US 7608261

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

US 7585879

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Sep 8, 2009 · Expires Sep 3, 2029

US 7585868

Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists

The Regents of the University of California · Granted Sep 8, 2009 · Expires Sep 3, 2029

US 7575742

Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Aug 18, 2009 · Expires Aug 13, 2029

US 7572893

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Aug 11, 2009 · Expires Aug 6, 2029

US 7572920

Benzimidazole derivative and use as a II receptor antagonist

Takeda Pharmaceutical Company Limited · Granted Aug 11, 2009 · Expires Aug 6, 2029

US 7569586

Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted Aug 4, 2009 · Expires Jul 30, 2029

US 7569588

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Aug 4, 2009 · Expires Jul 30, 2029

US 7566718

Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

Pharmacopeia Drug Discovery, Inc. · Granted Jul 28, 2009 · Expires Jul 23, 2029

US 7560469

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jul 14, 2009 · Expires Jul 9, 2029

US 7557212

Tricyclic derivatives as LTD4 antagonists

Laboratories Almirall, S.A. · Granted Jul 7, 2009 · Expires Jul 2, 2029

US 7557126

Diphenylmethyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jul 7, 2009 · Expires Jul 2, 2029

AU 2008340179

Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonists

AOP ORPHAN PHARMACEUTICALS AG [AT] · Granted Jul 2, 2009 · Expires Jun 27, 2029

US 7550595

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Jun 23, 2009 · Expires Jun 18, 2029

US 7544358

Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6

The Regents of the University of California · Granted Jun 9, 2009 · Expires Jun 4, 2029

US 7531500

Preventing airway mucus production by administration of EGF-R antagonists

The Regents of the University of California · Granted May 12, 2009 · Expires May 7, 2029

US 7531172

Methods of treating diseases with a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

US 7531173

Ophthalmic composition of a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. · Granted May 12, 2009 · Expires May 7, 2029

US 7528253

Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Theravance, Inc. · Granted May 5, 2009 · Expires Apr 30, 2029

US 7524962

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance, Inc. · Granted Apr 28, 2009 · Expires Apr 23, 2029